Evidence map›Paper›PMID 39514913›Full record

ArticleParkinsonism & related disorders2025

GBA1 T369M and Parkinson's disease - Further evidence of a lack of association in the Swedish population.

Kajsa Atterling Brolin, David Bäckström, Joel Wallenius, Ziv Gan-Or, Andreas Puschmann, Oskar Hansson, Maria Swanberg

Abstract read
PubMed Publisher
In one paragraph

Article in Parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

  • Update of
    Is2024
5 · Who and what money

Authors and funding

7 authors.

Kajsa Atterling BrolinTranslational Neurogenetics Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden; Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, EC1M 6BQ, London, UK. Electronic address: kajsa.brolin@med.lu.se.
David BäckströmDepartment of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
Joel WalleniusDivision of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund, Sweden.
Ziv Gan-OrDepartment of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada; Clinical Research Unit, The Neuro (Montreal Neurological Institute-Hospital), Montreal, Quebec, Canada; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
Andreas PuschmannDivision of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund, Sweden; SciLifeLab National Research Infrastructure, Lund University, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Maria SwanbergTranslational Neurogenetics Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variants in GBA1 are important genetic risk factors in Parkinson's disease (PD). GBA1 T369M has been linked to an ∼80 % increased PD risk but the reports are conflicting and the relevance of GBA1 variants in different populations varies. A lack of association between T369M and PD in the Swedish population was recently reported but needs further validation. We therefore investigated T369M in 1,808 PD patients and 2,183 controls and our results support that T369M is not a risk factor for PD in the Swedish population.

Indexed as

GlucosylceramidaseParkinson DiseaseAgedFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedSwedenGBA protein, humanGlucosylceramidase

Identifiers

PMID39514913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.